Richard Kent has become president and CEO of Serenex, based in Durham, NC. He succeeds Robert Dishman, the company’s founding president, CEO, and chairman.
Prior to joining Serenex, Kent was president and CEO of Ardent Pharmaceuticals. Before that, he held various positions at GlaxoSmith-Kline, including vice president for US medical operations, group medical director, vice president for global medical affairs, and chief medical officer.
Kent holds a BA from the University of California, Berkeley, and an MD from the University of California, San Diego, School of Medicine. He completed his training at Harvard University, Stanford University, and Duke University, and was on the medical staff at Duke University Medical Center before working at Burroughs Wellcome and Glaxo Wellcome in Research Triangle Park.
Kevin Sanborn has become president of Millipore’s life sciences divison, replacing William Emhiser. Previously, Sanborn was vice president of strategic planning and business development at Millipore, which is based in Bedford, Mass.
Prior to joining the company, Sanborn was a consultant at Bain & Company. Before that he was a financial analyst at Goldman, Sachs & Company. He holds an MBA from the Amos Tuck School of Business Administraton at Dartmouth College, and an AB in Economics from Bowdoin College.